{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:31:05Z","timestamp":1787563865673,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science and Technology Projects in Guangzhou","award":["2025A03J3474"],"award-info":[{"award-number":["2025A03J3474"]}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["21625311"],"award-info":[{"award-number":["21625311"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Shenzhen Fundamental Research Program","award":["JCYJ20240813112004006"],"award-info":[{"award-number":["JCYJ20240813112004006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-07882-z","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:35:34Z","timestamp":1772210134000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Microfluidic-based patient-derived organoids recapitulate thyroid cancer heterogeneity and reveal NF-\u03baB-driven maturation for precision therapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Hengyuan","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingshi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junchang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0345-0918","authenticated-orcid":false,"given":"Xiaoyong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"7882_CR1","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S0140-6736(23)00020-X","volume":"401","author":"D Chen","year":"2023","unstructured":"Chen D, Lang B, McLeod D, Newbold K. Haymart. Thyroid Cancer Lancet (London England). 2023;401:1531\u201344.","journal-title":"Thyroid Cancer Lancet (London England)"},{"key":"7882_CR2","first-page":"1","volume":"2","author":"R Zheng","year":"2022","unstructured":"Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2022;2:1\u20139.","journal-title":"J Natl Cancer Cent"},{"key":"7882_CR3","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1097\/CM9.0000000000003284","volume":"137","author":"Z Lyu","year":"2024","unstructured":"Lyu Z, Zhang Y, Sheng C, Huang Y, Zhang Q, Chen K. Global burden of thyroid cancer in 2022: incidence and mortality estimates from GLOBOCAN. Chin Med J. 2024;137:2567\u201376.","journal-title":"Chin Med J"},{"key":"7882_CR4","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1007\/s00268-005-0472-4","volume":"30","author":"CA Benbassat","year":"2006","unstructured":"Benbassat CA, Mechlis-Frish S, Hirsch D. Clinicopathological characteristics and long\u2010term outcome in patients with distant metastases from differentiated thyroid cancer. World J Surg. 2006;30:1088\u201395.","journal-title":"World J Surg"},{"key":"7882_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s12020-018-1713-2","volume":"63","author":"D Albano","year":"2019","unstructured":"Albano D, Panarotto MB, Durmo R, Rodella C, Bertagna F, Giubbini R. Clinical and prognostic role of detection timing of distant metastases in patients with differentiated thyroid cancer. Endocrine. 2019;63:79\u201386.","journal-title":"Endocrine"},{"key":"7882_CR6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/jama.2023.26348","volume":"331","author":"L Boucai","year":"2024","unstructured":"Boucai L, Zafereo M, Cabanillas ME. Thyroid cancer: a review. JAMA. 2024;331:425\u201335.","journal-title":"JAMA"},{"key":"7882_CR7","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1210\/er.2019-00007","volume":"40","author":"ME Cabanillas","year":"2019","unstructured":"Cabanillas ME, Ryder M, Jimenez C. Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr Rev. 2019;40:1573\u2013604.","journal-title":"Endocr Rev"},{"key":"7882_CR8","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1200\/OP.23.00747","volume":"20","author":"KM Yun","year":"2024","unstructured":"Yun KM, Cohen EE. An era of advances in systemic therapies for advanced thyroid cancer. JCO Oncol Pract. 2024;20:899\u2013906.","journal-title":"JCO Oncol Pract"},{"key":"7882_CR9","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1038\/s41467-022-29000-5","volume":"13","author":"P Zhang","year":"2022","unstructured":"Zhang P, Guan H, Yuan S, Cheng H, Zheng J, Zhang Z, Liu Y, Yu Y, Meng Z, Zheng X. Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors. Nat Commun. 2022;13:1588.","journal-title":"Nat Commun"},{"key":"7882_CR10","doi-asserted-by":"crossref","unstructured":"Karimi F, Aghaei M, Saki N. Impact of genetic polymorphisms on treatment outcomes of proteasome inhibitors and immunomodulatory drugs in multiple myeloma. Curr Treat Options Oncol. 2025:1\u201316.","DOI":"10.1007\/s11864-025-01295-8"},{"key":"7882_CR11","doi-asserted-by":"publisher","first-page":"6149","DOI":"10.1038\/s41467-022-33907-4","volume":"13","author":"K Rabold","year":"2022","unstructured":"Rabold K, Zoodsma M, Grondman I, Kuijpers Y, Bremmers M, Jaeger M, Zhang B, Hobo W, Bonenkamp HJ, de Wilt JH. Reprogramming of myeloid cells and their progenitors in patients with non-medullary thyroid carcinoma. Nat Commun. 2022;13:6149.","journal-title":"Nat Commun"},{"key":"7882_CR12","doi-asserted-by":"crossref","unstructured":"Toda S, Koike E, Aoki S, Uchihashi K, Koike N, Sugihara H. Culture system for studying thyroid biology. In International Congress Series. Elsevier. 2007:273\u2013280.","DOI":"10.1016\/j.ics.2006.09.020"},{"key":"7882_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.pharmthera.2017.10.018","volume":"184","author":"T Rodrigues","year":"2018","unstructured":"Rodrigues T, Kundu B, Silva-Correia J, Kundu SC, Oliveira JM, Reis RL, Correlo VM. Emerging tumor spheroids technologies for 3D in vitro cancer modeling. Pharmacol Ther. 2018;184:201\u201311.","journal-title":"Pharmacol Ther"},{"key":"7882_CR14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-018-0662-9","volume":"11","author":"H Xu","year":"2018","unstructured":"Xu H, Lyu X, Yi M, Zhao W, Song Y, Wu K. Organoid technology and applications in cancer research. J Hematol Oncol. 2018;11:116.","journal-title":"J Hematol Oncol"},{"key":"7882_CR15","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.3390\/cells10123295","volume":"10","author":"F Foglietta","year":"2021","unstructured":"Foglietta F, Serpe L, Canaparo R. The effective combination between 3D cancer models and stimuli-responsive nanoscale drug delivery systems. Cells. 2021;10:3295.","journal-title":"Cells"},{"key":"7882_CR16","doi-asserted-by":"publisher","first-page":"1140888","DOI":"10.3389\/fendo.2023.1140888","volume":"14","author":"H Yang","year":"2023","unstructured":"Yang H, Liang Q, Zhang J, Liu J, Wei H, Chen H, Wei W, Chen D, Zhao Y. Establishment of papillary thyroid cancer organoid lines from clinical specimens. Front Endocrinol. 2023;14:1140888.","journal-title":"Front Endocrinol"},{"key":"7882_CR17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nature07935","volume":"459","author":"T Sato","year":"2009","unstructured":"Sato T, Vries RG, Snippert HJ, Van De Wetering M, Barker N, Stange DE, Van Es JH, Abo A, Kujala P, Peters PJ. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459:262\u20135.","journal-title":"Nature"},{"key":"7882_CR18","doi-asserted-by":"publisher","first-page":"2302686","DOI":"10.1002\/adhm.202302686","volume":"13","author":"H Liu","year":"2024","unstructured":"Liu H, Gan Z, Qin X, Wang Y, Qin J. Advances in microfluidic technologies in organoid research. Adv Healthc Mater. 2024;13:2302686.","journal-title":"Adv Healthc Mater"},{"key":"7882_CR19","doi-asserted-by":"crossref","unstructured":"\u00d6zkayar G, L\u00f6tters JC, Tichem M, Ghatkesar MK. Toward a modular, integrated, miniaturized, and portable microfluidic flow control architecture for organs-on-chips applications. Biomicrofluidics. 2022;16.","DOI":"10.1063\/5.0074156"},{"key":"7882_CR20","doi-asserted-by":"crossref","unstructured":"Huang L, Cai Y, Luo Y, Xiong D, Hou Z, Lv J, Zeng F, Yang Y, Cheng X. JAZF1 suppresses papillary thyroid carcinoma cell proliferation and facilitates apoptosis via regulating TAK1\/NF-\u03baB pathways. OncoTargets Therapy. 2019:10501\u201314.","DOI":"10.2147\/OTT.S230597"},{"key":"7882_CR21","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3390\/cells9040830","volume":"9","author":"G Laetitia","year":"2020","unstructured":"Laetitia G, Sven S, Fabrice J. Combinatorial therapies in thyroid cancer: an overview of preclinical and clinical progresses. Cells. 2020;9:830.","journal-title":"Cells"},{"key":"7882_CR22","doi-asserted-by":"publisher","first-page":"bqac187","DOI":"10.1210\/endocr\/bqac187","volume":"164","author":"D Huang","year":"2023","unstructured":"Huang D, Zeng Y, Deng H-Y, Fu B-D, Ke Y, Luo J-Y, Yu J-C, Yu S-T. SYTL5 promotes papillary thyroid carcinoma progression by enhancing activation of the NF-\u03baB signaling pathway. Endocrinology. 2023;164:bqac187.","journal-title":"Endocrinology"},{"key":"7882_CR23","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.3390\/cancers12113212","volume":"12","author":"LH Sondorp","year":"2020","unstructured":"Sondorp LH, Ogundipe VM, Groen AH, Kelder W, Kemper A, Links TP, Coppes RP, Kruijff S. Patient-derived papillary thyroid cancer organoids for radioactive iodine refractory screening. Cancers. 2020;12:3212.","journal-title":"Cancers"},{"key":"7882_CR24","doi-asserted-by":"publisher","first-page":"101393","DOI":"10.1016\/j.xpro.2022.101393","volume":"3","author":"V Pecce","year":"2022","unstructured":"Pecce V, Sponziello M, Bini S, Grani G, Durante C, Verrienti A. Establishment and maintenance of thyroid organoids from human cancer cells. STAR Protocols. 2022;3:101393.","journal-title":"STAR Protocols"},{"key":"7882_CR25","doi-asserted-by":"crossref","unstructured":"Yang H, Li J, Zheng Y, Cao Y, Zhu Y, Sang G, Galan EA, Ruan C, Ma WM, Dai X. Ultra-small tissue-compatible organoid printer for rapid and controllable modeling of respiratory organoids. Device. 2024;2.","DOI":"10.1016\/j.device.2024.100420"},{"key":"7882_CR26","doi-asserted-by":"crossref","unstructured":"Verbeek HH, de Groot JWB, Sluiter WJ, Kobold ACM, van den Heuvel ER, Plukker JT, Links TP. Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodules. Cochrane database of systematic reviews. 2020.","DOI":"10.1002\/14651858.CD010159.pub2"},{"key":"7882_CR27","doi-asserted-by":"publisher","first-page":"18125","DOI":"10.1038\/s41598-024-69187-9","volume":"14","author":"X Li","year":"2024","unstructured":"Li X, Jian J, Zhang A, Xiang Jm, Huang J, Chen Y. The role of immune cells and immune related genes in the tumor microenvironment of papillary thyroid cancer and their significance for immunotherapy. Sci Rep. 2024;14:18125.","journal-title":"Sci Rep"},{"key":"7882_CR28","doi-asserted-by":"publisher","first-page":"102372","DOI":"10.1016\/j.ctrv.2022.102372","volume":"105","author":"M San Roman-Gil","year":"2022","unstructured":"San Roman-Gil M, Pozas J, Rosero-Rodriguez D, Chamorro-Perez J, Ruiz-Granados A, Caracuel IR, Grande E, Molina-Cerrillo J, Alonso-Gordoa T. Resistance to RET targeted therapy in thyroid cancer: molecular basis and overcoming strategies. Cancer Treat Rev. 2022;105:102372.","journal-title":"Cancer Treat Rev"},{"key":"7882_CR29","doi-asserted-by":"publisher","first-page":"18163","DOI":"10.18632\/aging.103645","volume":"12","author":"Z Xie","year":"2020","unstructured":"Xie Z, Lun Y, Li X, He Y, Wu S, Wang S, Sun J, He Y, Zhang J. Bioinformatics analysis of the clinical value and potential mechanisms of AHNAK2 in papillary thyroid carcinoma. Aging. 2020;12:18163.","journal-title":"Aging"},{"key":"7882_CR30","doi-asserted-by":"publisher","first-page":"723777","DOI":"10.3389\/fcell.2021.723777","volume":"9","author":"W-L Liu","year":"2021","unstructured":"Liu W-L, Guan Q, Wen D, Ma B, Xu W-B, Hu J-Q, Wei W-J, Li D-S, Wang Y, Xiang J. PRDM16 inhibits cell proliferation and migration via epithelial-to-mesenchymal transition by directly targeting pyruvate carboxylase in papillary thyroid cancer. Front Cell Dev Biology. 2021;9:723777.","journal-title":"Front Cell Dev Biology"},{"key":"7882_CR31","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/cen.13489","volume":"88","author":"SY Sohn","year":"2018","unstructured":"Sohn SY, Kim HI, Kim YN, Kim TH, Kim SW, Chung JH. Prognostic indicators of outcomes in patients with lung metastases from differentiated thyroid carcinoma during long-term follow\u2010up. Clin Endocrinol. 2018;88:318\u201326.","journal-title":"Clin Endocrinol"},{"key":"7882_CR32","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3389\/fendo.2019.00903","volume":"10","author":"Z-L Qiu","year":"2020","unstructured":"Qiu Z-L, Shen C-T, Sun Z-K, Song H-J, Zhang G-Q, Luo Q-Y. Lung metastases from papillary thyroid cancer with persistently negative thyroglobulin and elevated thyroglobulin antibody levels during radioactive iodine treatment and follow-up: long-term outcomes and prognostic indicators. Front Endocrinol. 2020;10:903.","journal-title":"Front Endocrinol"},{"key":"7882_CR33","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1210\/clinem\/dgab020","volume":"106","author":"D Chen","year":"2021","unstructured":"Chen D, Tan Y, Li Z, Li W, Yu L, Chen W, Liu Y, Liu L, Guo L, Huang W. Organoid cultures derived from patients with papillary thyroid cancer. J Clin Endocrinol Metabolism. 2021;106:1410\u201326.","journal-title":"J Clin Endocrinol Metabolism"},{"key":"7882_CR34","doi-asserted-by":"publisher","first-page":"4884","DOI":"10.7150\/jca.44506","volume":"11","author":"H Yin","year":"2020","unstructured":"Yin H, Tang Y, Guo Y, Wen S. Immune microenvironment of thyroid cancer. J Cancer. 2020;11:4884.","journal-title":"J Cancer"},{"key":"7882_CR35","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1007\/s43032-024-01676-8","volume":"31","author":"SS Bahreiny","year":"2024","unstructured":"Bahreiny SS, Ahangarpour A, Rajaei E, Sharifani MS, Aghaei M. Meta-analytical and meta-regression evaluation of subclinical hyperthyroidism\u2019s effect on male reproductive health: hormonal and seminal perspectives. Reproductive Sci. 2024;31:2957\u201371.","journal-title":"Reproductive Sci"},{"key":"7882_CR36","doi-asserted-by":"crossref","unstructured":"Aliazis K, Christofides A, Shah R, Yeo YY, Jiang S, Charest A, Boussiotis VA. The tumor microenvironment\u2019s role in the response to immune checkpoint Blockade. Nat Cancer. 2025:1\u201314.","DOI":"10.1038\/s43018-025-00986-3"},{"key":"7882_CR37","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s10238-025-01751-7","volume":"25","author":"NS Sherafat","year":"2025","unstructured":"Sherafat NS, Keshavarz A, Mardi A, Mohammadiara A, Aghaei M, Aghebati-Maleki L, Mohammadi MH. Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective. Clin Experimental Med. 2025;25:238.","journal-title":"Clin Experimental Med"},{"key":"7882_CR38","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","volume":"175","author":"JT Neal","year":"2018","unstructured":"Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, Liu IH, Chiou S-H, Salahudeen AA, Smith AR. Organoid modeling of the tumor immune microenvironment. Cell. 2018;175:1972\u201388. e1916.","journal-title":"Cell"},{"key":"7882_CR39","doi-asserted-by":"crossref","unstructured":"Dijkstra KK, Monkhorst K, Schipper LJ, Hartemink KJ, Smit EF, Kaing S, de Groot R, Wolkers MC, Clevers H, Cuppen E. Challenges in Establishing pure lung cancer organoids limit their utility for personalized medicine. Cell Rep. 2020;31.","DOI":"10.1016\/j.celrep.2020.107588"},{"key":"7882_CR40","doi-asserted-by":"publisher","first-page":"156065","DOI":"10.1016\/j.metabol.2024.156065","volume":"162","author":"H Wang","year":"2025","unstructured":"Wang H, Zhu W, Xu C, Su W, Li Z. Engineering organoids-on-chips for drug testing and evaluation. Metabolism. 2025;162:156065.","journal-title":"Metabolism"},{"key":"7882_CR41","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41413-024-00376-y","volume":"12","author":"L Bai","year":"2024","unstructured":"Bai L, Zhou D, Li G, Liu J, Chen X, Su J. Engineering bone\/cartilage organoids: strategy, progress, and application. Bone Res. 2024;12:66.","journal-title":"Bone Res"},{"key":"7882_CR42","doi-asserted-by":"publisher","first-page":"115271","DOI":"10.1016\/j.bios.2023.115271","volume":"231","author":"AG Monteduro","year":"2023","unstructured":"Monteduro AG, Rizzato S, Caragnano G, Trapani A, Giannelli G, Maruccio G. Organs-on-chips technologies\u2013A guide from disease models to opportunities for drug development. Biosens Bioelectron. 2023;231:115271.","journal-title":"Biosens Bioelectron"},{"key":"7882_CR43","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1210\/jc.2018-01690","volume":"104","author":"AS Alzahrani","year":"2019","unstructured":"Alzahrani AS, Alswailem M, Moria Y, Almutairi R, Alotaibi M, Murugan AK, Qasem E, Alghamdi B, Al-Hindi H. Lung metastasis in pediatric thyroid cancer: radiological pattern, molecular genetics, response to therapy, and outcome. J Clin Endocrinol Metabolism. 2019;104:103\u201310.","journal-title":"J Clin Endocrinol Metabolism"},{"key":"7882_CR44","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1089\/thy.2020.0002","volume":"31","author":"AD Chesover","year":"2021","unstructured":"Chesover AD, Vali R, Hemmati SH, Wasserman JD. Lung metastasis in children with differentiated thyroid cancer: factors associated with diagnosis and outcomes of therapy. Thyroid. 2021;31:50\u201360.","journal-title":"Thyroid"},{"key":"7882_CR45","doi-asserted-by":"publisher","first-page":"284","DOI":"10.14740\/jocmr2480w","volume":"8","author":"S Jin","year":"2016","unstructured":"Jin S, Borkhuu O, Bao W, Yang Y-T. Signaling pathways in thyroid cancer and their therapeutic implications. J Clin Med Res. 2016;8:284.","journal-title":"J Clin Med Res"},{"key":"7882_CR46","doi-asserted-by":"publisher","first-page":"11464","DOI":"10.3390\/ijms252111464","volume":"25","author":"E Crescenzi","year":"2024","unstructured":"Crescenzi E, Leonardi A, Pacifico F. NF-\u03baB in thyroid cancer: an update. Int J Mol Sci. 2024;25:11464.","journal-title":"Int J Mol Sci"},{"key":"7882_CR47","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1210\/jc.2003-031216","volume":"89","author":"D Starenki","year":"2004","unstructured":"Starenki D, Namba H, Saenko V, Ohtsuru A, Yamashita S. Inhibition of nuclear factor-\u03baB cascade potentiates the effect of a combination treatment of anaplastic thyroid cancer cells. J Clin Endocrinol Metabolism. 2004;89:410\u20138.","journal-title":"J Clin Endocrinol Metabolism"},{"key":"7882_CR48","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1476-4598-9-117","volume":"9","author":"KT Bauerle","year":"2010","unstructured":"Bauerle KT, Schweppe RE, Haugen BR. Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion. Mol Cancer. 2010;9:117.","journal-title":"Mol Cancer"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07882-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07882-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07882-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T13:01:32Z","timestamp":1775221292000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07882-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7882"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07882-z","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics approval of this study was derived from the project of \u201cMechanism of PUS10-mediated pseudouridylation of pre-mir-152 in papillary thyroid carcinogenesis and progression via the PRR15-PI3K\/Akt axis\u201d, which was approved by the Scientific Research Ethics Committee of the First Affiliated Hospital of Jinan University (Ethical Development No. KY-2024-308).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agreed on the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"467"}}